Program
survodutide
Also written as “Survodutide”, “BI 456906” and “Survodutide formulation A”.
In Boehringer Ingelheim's pipeline, GCGR/GLP1 agonist
. Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Fatty Liver · Liver Cirrhosis · Renal Insufficiency, led by Boehringer Ingelheim.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 3510 open or running | phase 3since Sep 27, 2023 | Jun 1, 2017 | Dec 8, 2026phase 1 · NCT07768813 |
- Named in Boehringer Ingelheim’s own pipeline as
Survodutide (BI 456906)
, phase 3, as of Aug 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Jun 1, 2017.
- Apr 3, 20242 phase 1 studiesNCT06352424, NCT06352411
- Jul 1, 2024Phase 1 study in OverweightNCT06492135 · 30 enrolled · China
- Aug 20, 2024Phase 1 study in OverweightNCT06564441 · 34 enrolled · Belgium
- Oct 8, 20242 phase 3 studiesNCT06632457, NCT06632444
- Dec 19, 2024Phase 1 study in ObesityNCT06745284 · 64 enrolled · United States
- Jan 10, 2025Phase 1 study in HealthyNCT06772532 · 30 enrolled · Germany
- Jul 16, 2025Phase 1 study in HealthyNCT07071974 · 16 enrolled · Germany
- Oct 27, 2025Phase 1 study in HealthyNCT07221591 · 100 enrolled · Germany
- Feb 10, 2026Phase 1 study in ObesityNCT07413913 · 56 enrolled · Germany
- Aug 5, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07754461 · 600 planned · United States, Australia, Canada and more
- Aug 12, 2026Phase 1 study in ObesityNCT07768813 · 44 enrolled · Germany
- Sep 25, 20263 phase 3 studies in ObesityNCT07850063, NCT07850050, NCT07855900
- Oct 27, 2026Primary completion moved from 2028-06-25 to 2029-11-06Date moved laterphase 3 · +16 months · NCT07855900
- Nov 9, 2026Phase 1 study in ObesityNCT07940244 · 80 planned · Germany
Ahead
- Nov 1, 2026Primary completion: phase 1 study in ObesityNCT06745284
- Dec 8, 2026Primary completion: phase 1 study in ObesityNCT07768813
- Jan 6, 2027Primary completion: phase 1 study in ObesityNCT05202353
- Oct 31, 2027Primary completion: phase 1 study in ObesityNCT07940244
TargetBeta
“GCGR/GLP1 agonist”the company's pipeline, read by Claude · source
“Glucagon-like peptide 1 receptor agonist; Glucagon receptor agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| UBT251 | The United Laboratories International | phase 3 | 12 |
| DR10624rule | Huadong Medicine | phase 3 | 6 |
| efinopegdutide | Johnson & Johnson | phase 2 | 15 |
| AZD9550 | AstraZeneca | phase 2 | 7 |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 5 |
Studies
All 35 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07940244Obesity · Germany | 1 | Not yet recruiting | Oct 31, 2027 | 80 |
| NCT07855900Obesity · United States | 3 | Not yet recruiting | Nov 6, 2029 | 350 |
| NCT07850063Obesity · United States, China, Germany and more | 3 | Not yet recruiting | Apr 29, 2029 | 600 |
| NCT07850050Obesity · United States, United Kingdom | 3 | Not yet recruiting | Jul 26, 2028 | 600 |
| NCT07768813Obesity · Germany | 1 | Active, not recruiting | Dec 8, 2026 | 44 |
| NCT07754461Diabetes Mellitus, Type 2 · United States, Australia, Canada and more | 3 | Recruiting | Jan 17, 2028 | 600 |
| NCT07413913Obesity · Germany | 1 | Completed | May 28, 2026 | 56 |
| NCT07221591Healthy · Germany | 1 | Completed | Jul 28, 2026 | 100 |
| NCT07071974Healthy · Germany | 1 | Completed | Oct 7, 2025 | 16 |
| NCT06772532Healthy · Germany | 1 | Completed | May 29, 2025 | 30 |
| NCT06745284Obesity · United States | 1 | Active, not recruiting | Nov 1, 2026 | 64 |
| NCT06632457Metabolic Dysfunction Associated Steatohepatitis · United States, Argentina, Australia and more | 3 | Recruiting | Jun 5, 2029 | 1,590 |
| NCT06632444Liver Cirrhosis · United States, Argentina, Australia and more | 3 | Recruiting | Dec 27, 2031 | 1,800 |
| NCT06564441Overweight · Belgium | 1 | Completed | Dec 16, 2025 | 34 |
| NCT06492135Overweight · China | 1 | Completed | Apr 15, 2025 | 30 |
| NCT06352424Obesity · Germany | 1 | Completed | Feb 24, 2025 | 23 |
| NCT06352411Renal Insufficiency · Germany | 1 | Completed | Sep 16, 2025 | 42 |
| NCT06309992Obesity · United States, Spain | 3 | Completed | Oct 9, 2025 | 218 |
| NCT06214741Obesity · China | 3 | Completed | Jul 29, 2025 | 307 |
| NCT06200467Overweight · Germany | 1 | Completed | Oct 22, 2025 | 110 |
| NCT06176365Obesity · Japan | 3 | Completed | Dec 3, 2025 | 274 |
| NCT06077864Obesity · United States, Argentina, Australia and more | 3 | Completed | Jun 1, 2026 | 5,530 |
| NCT06066528Obesity · United States, Australia, Belgium and more | 3 | Completed | Dec 12, 2025 | 755 |
| NCT06066515Obesity · United States, Australia, Belgium and more | 3 | Completed | Dec 2, 2025 | 726 |
| NCT05896384Healthy · Germany | 1 | Completed | Feb 14, 2025 | 32 |
| NCT05751226Obesity · Germany | 1 | Completed | Aug 1, 2024 | 88 |
| NCT05421338Healthy · Netherlands | 1 | Completed | Nov 17, 2022 | 6 |
| NCT05296733Liver Diseases · United States, Germany, Hungary and more | 1 | Completed | Dec 29, 2023 | 82 |
| NCT05202353Obesity · Netherlands | 1 | Active, not recruiting | Jan 6, 2027 | 29 |
| NCT04771273Non-alcoholic Fatty Liver Disease · United States, Australia, Austria and more | 2 | Completed | Nov 9, 2023 | 295 |
| NCT04667377Obesity · United States, Australia, Belgium and more | 2 | Completed | Sep 15, 2022 | 387 |
| NCT04384081Healthy · Japan | 1 | Completed | Nov 17, 2020 | 37 |
| NCT04153929Diabetes Mellitus, Type 2 · United States, Australia, Austria and more | 2 | Completed | Oct 8, 2021 | 413 |
| NCT03591718Obesity · Germany | 1 | Completed | Apr 20, 2020 | 131 |
| NCT03175211Healthy · Germany | 1 | Completed | Feb 19, 2018 | 20 |
How it is read
Names in the registry
- “Survodutide”, 12 entries
- “BI 456906”, 12 entries
- “survodutide”, 5 entries
- “Survodutide formulation A”, 3 entries
- “Survodutide formulation B2”, 2 entries
Conditions, from the studies’ own filings
- Obesity, 21 studies
- Diabetes Mellitus, Type 2, 2 studies
- Fatty Liver, 1 study
- Liver Cirrhosis, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.